When do psychiatric side effects emerge during antiviral treatment of hepatitis C?

BACKGROUND This retrospective study aimed to determine the time-frame regarding the first appearance of psychiatric side effects in the course of antiviral treatment and the subsequent referral to consultation-liaison psychiatric services. SUBJECTS AND METHODS Medical records of patients receiving combined antiviral treatment with alpha interferon and ribavirin for hepatitis C at a hepatology outpatient clinic and referred to psychiatric consultation between April 2000 and July 2011 were scrutinized. RESULTS Time between the initiation of antiviral treatment and the first appearance of psychiatric symptoms was 10.64±10.68 weeks. Patients were referred to psychiatric examination 16.1±12.7 weeks after antiviral treatment had been commenced. The time frame of the emergence of psychiatric symptoms and the referral for psychiatric consultation did not correlate with the patients' age or sex. No relationship between substance/alcohol abuse and psychiatric history and the timing of psychiatric side effects and their assessment were found. CONCLUSIONS This study confirmed that psychiatric side effects appear late in the course of combined antiviral treatment arising after 10.64±10.68 weeks the treatment started. The results also showed that some patients' psychiatric symptoms appeared immediately after the beginning of the antiviral therapy. This finding underlines the importance of monitoring patients' psychiatric condition as soon as antiviral treatment commences.

[1]  D. Delić,et al.  Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. , 2011, Psychiatria Danubina.

[2]  P. Links,et al.  Suicide risk in hepatitis C and during interferon‐alpha therapy: a review and clinical update , 2011, Journal of viral hepatitis.

[3]  L. Quarantini,et al.  Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. , 2010, General hospital psychiatry.

[4]  A. Lopes,et al.  Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review , 2009, Journal of psychiatric practice.

[5]  R. Bressan,et al.  Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report. , 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[6]  A. Heinz,et al.  Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. , 2005, Journal of hepatology.

[7]  C. Nemeroff,et al.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. , 2005, The Journal of clinical psychiatry.

[8]  P. Hauser,et al.  The phenomenology and treatment of interferon-induced depression. , 2004, Journal of affective disorders.

[9]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[10]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[11]  M. Willenbring,et al.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. , 2000, The American journal of psychiatry.

[12]  David H. Lee,et al.  Morbidity of Chronic Hepatitis C as Seen in a Tertiary Care Medical Center , 2004, Digestive Diseases and Sciences.